More about MedPlus Health Services Limited
Fundamentals for MedPlus Health Services Limited
Regulatory Filings for MedPlus Health Services Limited
IndiGo Implements Steep Fuel Surcharge as Iran Conflict Sends Jet Fuel Costs Soaring
The RBI's New Forex Fortress: Defensive Maneuvers in an Era of Oil Shocks
India's Fiscal Milestone: GST Collections Breach ₹2 Lakh Crore Mark for the First Time
AI Disruption Accelerates: Oracle Layoffs Raise Alarms for India’s Tech Workforce
Fundamentals for MedPlus Health Services Limited
Business Operations:
Sector: HealthcareIndustry: Pharmaceutical Retailers
MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It manufactures and trades in pharmaceutical and wellness products, comprising medicines, vitamins, medical devices, and test kits; and offers consumer goods, such as home and personal care products, including toiletries, baby care products, soaps and detergents, and sanitizers. The company also provides wholesale cash and carry; diagnostic, pathological, and laboratory testing services, as well as engages in the contract manufacturing of private label pharmaceuticals. It operates stores in Telangana, Andhra Pradesh, Karnataka, Tamil Nadu, West Bengal, Maharashtra, Orissa, Madhya Pradesh, Chhattisgarh, Kerala, and Puducherry, as well as online platform. The company was incorporated in 2006 and is based in Hyderabad, India.
Revenue projections:
Investors are expected to be cautious with MEDPLUS, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.
Financial Ratios:
| currentRatio | 2.90300 |
|---|---|
| forwardPE | 39.13855 |
| debtToEquity | 64.68900 |
| earningsGrowth | 0.43000 |
| revenueGrowth | 0.06500 |
| grossMargins | 0.25567 |
| operatingMargins | 0.04781 |
| trailingEps | 16.28000 |
| forwardEps | 19.81167 |
MEDPLUS's current ratio is 2.903, showing the company's capacity to service its short-term debt through its cash reserves and current assets. This is a positive indicator of liquidity, suggesting MEDPLUS has no trouble covering its short-term financial obligations.
MEDPLUS's forward EPS surpassing its trailing EPS signals that the company is anticipated to be more profitable this year than last. This growth expectation highlights MEDPLUS's potential for increased earnings and a stronger financial performance in the upcoming year.
Price projections:
The current price of MEDPLUS, in relation to its projections, presents a neutral outlook. There are no discernible risks or opportunities at this stage, indicating that investors may need to await further developments to make informed decisions regarding their positions in the stock.
Recommendation changes over time:
Analysts have shown a buy bias for MEDPLUS, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to MEDPLUS, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
U.S. Labor Market in 2026: JOLTS and Consumer Confidence Reveal Why Hiring Cooled Without Unemployment Spike
Lending Unleashed: Assessing the Impact of the Federal Reserve’s Capital Rollback
Calendar Collision: How Mahavir Jayanti's Overlap With Fiscal Year-End Reshapes India's Tax-Loss Harvesting Landscape